Abstract
Alexion, a rare disease–focused group within AstraZeneca, will acquire the genomic medicine company LogicBio Therapeutics. Alexion says it is interested in LogicBio’s technology for delivering and inserting genes using adeno-associated viruses to address rare genetic diseases. Alexion is paying $2.07 per share, or about $70 million—well over LogicBio’s share price of less than 50 cents before the deal was announced.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
